Drug Profile


Alternative Names: PD 0348292; PD 348292

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antithrombotics; Pyridones; Pyrrolidines; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Venous thrombosis

Most Recent Events

  • 08 Feb 2010 Discontinued - Phase-II for Venous thrombosis in USA (PO)
  • 07 Nov 2007 Pharmacodynamics data from a preclinical iliac venous stenting study presented at the 80th Scientific Sessions of the American Heart Association (AHA-2007)
  • 22 May 2006 Phase-II clinical trials in Venous thrombosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top